Cargando…

Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers

SIMPLE SUMMARY: Immune therapy using checkpoint inhibitors has been increasing in genitourinary cancers for the past decade, starting with monotherapy in renal cell carcinoma and urothelial carcinoma to now include many first-line combinations. More combinations and FDA/EMA indications are undoubted...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Haoran, Sahu, Kamal K., Maughan, Benjamin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139183/
https://www.ncbi.nlm.nih.gov/pubmed/35626064
http://dx.doi.org/10.3390/cancers14102460
_version_ 1784714799622389760
author Li, Haoran
Sahu, Kamal K.
Maughan, Benjamin L.
author_facet Li, Haoran
Sahu, Kamal K.
Maughan, Benjamin L.
author_sort Li, Haoran
collection PubMed
description SIMPLE SUMMARY: Immune therapy using checkpoint inhibitors has been increasing in genitourinary cancers for the past decade, starting with monotherapy in renal cell carcinoma and urothelial carcinoma to now include many first-line combinations. More combinations and FDA/EMA indications are undoubtedly on the horizon. An increasing number of patients will be treated with these therapies in the future resulting in a significant increase in the prevalence of immune mediated toxicities. This manuscript focuses on the current understanding of immunotherapy related adverse effects in genitourinary malignancies encountered with the use of immune checkpoint inhibitors. ABSTRACT: The use of immune checkpoint inhibitors (ICIs) is rapidly increasing as more combinations and clinical indications are approved in the field of genitourinary malignancies. Most immunotherapeutic agents being approved are for the treatment of renal cell carcinoma and bladder cancer, which mainly involve PD-1/PD-L1 and CTLA-4 pathways. There is an ongoing need for recognizing and treating immunotherapy-related autoimmune adverse effects (irAEs). This review aims to critically appraise the recent literature on the mechanism, common patterns, and treatment recommendations of irAEs in genitourinary malignancies. We review the epidemiology of these adverse effects as well as general treatment strategies. The underlying mechanisms will also be discussed. Diagnostic considerations including differential diagnosis are also included in this review.
format Online
Article
Text
id pubmed-9139183
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91391832022-05-28 Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers Li, Haoran Sahu, Kamal K. Maughan, Benjamin L. Cancers (Basel) Review SIMPLE SUMMARY: Immune therapy using checkpoint inhibitors has been increasing in genitourinary cancers for the past decade, starting with monotherapy in renal cell carcinoma and urothelial carcinoma to now include many first-line combinations. More combinations and FDA/EMA indications are undoubtedly on the horizon. An increasing number of patients will be treated with these therapies in the future resulting in a significant increase in the prevalence of immune mediated toxicities. This manuscript focuses on the current understanding of immunotherapy related adverse effects in genitourinary malignancies encountered with the use of immune checkpoint inhibitors. ABSTRACT: The use of immune checkpoint inhibitors (ICIs) is rapidly increasing as more combinations and clinical indications are approved in the field of genitourinary malignancies. Most immunotherapeutic agents being approved are for the treatment of renal cell carcinoma and bladder cancer, which mainly involve PD-1/PD-L1 and CTLA-4 pathways. There is an ongoing need for recognizing and treating immunotherapy-related autoimmune adverse effects (irAEs). This review aims to critically appraise the recent literature on the mechanism, common patterns, and treatment recommendations of irAEs in genitourinary malignancies. We review the epidemiology of these adverse effects as well as general treatment strategies. The underlying mechanisms will also be discussed. Diagnostic considerations including differential diagnosis are also included in this review. MDPI 2022-05-17 /pmc/articles/PMC9139183/ /pubmed/35626064 http://dx.doi.org/10.3390/cancers14102460 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Li, Haoran
Sahu, Kamal K.
Maughan, Benjamin L.
Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
title Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
title_full Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
title_fullStr Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
title_full_unstemmed Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
title_short Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
title_sort mechanism and management of checkpoint inhibitor-related toxicities in genitourinary cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139183/
https://www.ncbi.nlm.nih.gov/pubmed/35626064
http://dx.doi.org/10.3390/cancers14102460
work_keys_str_mv AT lihaoran mechanismandmanagementofcheckpointinhibitorrelatedtoxicitiesingenitourinarycancers
AT sahukamalk mechanismandmanagementofcheckpointinhibitorrelatedtoxicitiesingenitourinarycancers
AT maughanbenjaminl mechanismandmanagementofcheckpointinhibitorrelatedtoxicitiesingenitourinarycancers